Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Cash from Financing Activities (2018 - 2025)

Historic Cash from Financing Activities for Bicycle Therapeutics (BCYC) over the last 8 years, with Q3 2025 value amounting to -$30000.0.

  • Bicycle Therapeutics' Cash from Financing Activities rose 9990.6% to -$30000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $87000.0, marking a year-over-year decrease of 9998.33%. This contributed to the annual value of $519.8 million for FY2024, which is 10787.75% up from last year.
  • As of Q3 2025, Bicycle Therapeutics' Cash from Financing Activities stood at -$30000.0, which was up 9990.6% from -$45000.0 recorded in Q2 2025.
  • Bicycle Therapeutics' Cash from Financing Activities' 5-year high stood at $549.6 million during Q2 2024, with a 5-year trough of -$31.9 million in Q3 2024.
  • Over the past 5 years, Bicycle Therapeutics' median Cash from Financing Activities value was $1.9 million (recorded in 2024), while the average stood at $57.7 million.
  • In the last 5 years, Bicycle Therapeutics' Cash from Financing Activities skyrocketed by 370285000.0% in 2021 and then tumbled by 11360.86% in 2024.
  • Bicycle Therapeutics' Cash from Financing Activities (Quarter) stood at $190.7 million in 2021, then crashed by 96.91% to $5.9 million in 2022, then crashed by 93.44% to $386000.0 in 2023, then crashed by 47.41% to $203000.0 in 2024, then plummeted by 114.78% to -$30000.0 in 2025.
  • Its last three reported values are -$30000.0 in Q3 2025, -$45000.0 for Q2 2025, and -$41000.0 during Q1 2025.